Table 2 Proportion of patients treated with bevacizumab among patients who received chemotherapy, and predictors of treatment with bevacizumab in first line, adjusted for all factors listed (n = 361)

Gender

 Male

72

(49)

Ref

 Female

113

(53)

1.3

0.79–2.16

Age (years)

  < 60

57

(60)

Ref

 60–74

111

(56)

1.1

0.61–2.05

  ≥ 75

17

(26)

0.5

0.22–1.27

Comorbidity

 No

81

(62)

Ref

 1 comorbid condition

56

(54)

0.8

0.42–1.45

  ≥ 2 comorbid conditions

33

(34)

0.4

0.21–0.81

 Unknown

15

(48)

0.7

0.27–1.65

Primary tumor localization

 Rectum

85

(55)

Ref

 Colon

100

(48)

0.9

0.37–2.26

Adjuvant chemotherapy

 No

100

(49)

Ref

 Yes

85

(54)

1.7

0.98–2.96

Time to metastases (years)

  < 1 year

43

(43)

Ref

 1–2 years

71

(55)

1.5

0.78–2.82

  ≥ 2 years

71

(53)

1.2

0.60–2.30

Period of diagnosis metastasis

 2005–2006

41

(37)

Ref

 2007–2008

78

(58)

3.0

1.62–5.70

 2009–2011

66

(57)

3.3

1.67–6.74

Number of organs affected

 1 organ

85

(54)

Ref

 2 organs

59

(46)

0.5

0.29–0.91

  ≥ 3 organs

41

(53)

0.9

0.46–1.74

First-line chemotherapy

 Single agent chemotherapy

32

(23)

Ref

 Combination chemotherapy

153

(70)

9.6

5.43–17.05